Genmab Showcases Epcoritamab Breakthroughs for B-Cell Malignancies at ASH Meeting

Breakthroughs in B-Cell Malignancy Treatment Highlighted at ASH Meeting

Genmab A/S is set to make a significant impact at the upcoming 66th Annual Meeting and Exposition of the American Society of Hematology (ASH) in San Diego, California, which runs from December 7-10. The company announces the presentation of over 20 abstracts, including four oral presentations, that spotlight new clinical findings from its EPCORE® clinical trial program. Central to these discussions is epcoritamab-bysp (EPKINLY®), a T-cell engaging bispecific antibody that targets various B-cell malignancies, marking a crucial development in the treatment landscape for these conditions.

Among the noteworthy highlights of Genmab’s presentations are three oral talks that delve into the efficacy of subcutaneous epcoritamab in patients with previously untreated diffuse large B-cell lymphoma (DLBCL), large B-cell lymphoma (LBCL), and relapsed/refractory follicular lymphoma (FL). These studies underscore the potential of epcoritamab to offer novel therapeutic options for patients who have limited treatment alternatives. Additionally, the company will present compelling data from the EPCORE NHL-1 trial, which details three-year efficacy and safety outcomes for this therapy in relapsed/refractory DLBCL patients. The excitement surrounding these data reflects Genmab’s commitment to enhancing treatment protocols and improving patient outcomes in a challenging therapeutic area.

Dr. Judith Klimovsky, Executive Vice President and Chief Development Officer at Genmab, expresses optimism regarding the clinical results emerging from the epcoritamab trials. She emphasizes the strategic partnership with AbbVie in advancing this innovative therapy, which aims to broaden treatment options for patients battling B-cell malignancies. Following the ASH meeting, Genmab plans to conduct a virtual 2024 R&D Update and ASH Data Review on December 11, where they will further discuss the latest findings and developments surrounding epcoritamab. This focus on delivering robust clinical data positions Genmab as a key player in the oncology space, particularly in addressing the needs of patients with B-cell malignancies.

In addition to the notable presentations, all abstracts accepted for the ASH conference have been made publicly available on the ASH website, ensuring that the medical community can access this pivotal information. Genmab’s dedication to advancing cancer therapy is evident in its strategic initiatives and ongoing research, reflecting a promising future for patients facing B-cell malignancies. The upcoming ASH meeting serves as a platform not only to showcase these advancements but also to engage with healthcare professionals about the evolving landscape of treatment options.